

**UNITED STATES JUDICIAL PANEL**  
**on**  
**MULTIDISTRICT LITIGATION**

**IN RE: FRESENIUS GRANUFLO/NATURALYTE  
DIALYSATE PRODUCTS LIABILITY LITIGATION**

MDL No. 2428

**TRANSFER ORDER**

**Before the Panel:**\* Pursuant to Panel Rule 7.1, plaintiffs in the two actions listed on Schedule A—one of which is pending in the Central District of California (*Ajaryan*) and the other in the Eastern District of Missouri (*Payton*)—move to vacate our orders that conditionally transferred their respective actions to the District of Massachusetts for inclusion in MDL No. 2428. All responding defendants (hereafter, Fresenius)<sup>1</sup> oppose the motions.

In their motions to vacate, plaintiffs in both actions principally argue that transfer should not take place unless and until their pending motions for remand to state court are denied. We have held repeatedly, however, that a motion for remand alone is generally an insufficient basis to vacate a conditional transfer order.<sup>2</sup> Indeed, we have rejected similar arguments in support of motions to vacate conditional transfer orders in this litigation. *See, e.g., In re Fresenius GranuFlo/NaturaLyte Dialysate Prods. Liab. Litig.*, MDL No. 2428, ECF No. 413 (J.P.M.L. Dec. 13, 2013) (Transfer Order). The *Ajaryan* plaintiffs can present their motion for remand to the transferee judge. *See, e.g., In re Ivy*, 901 F.2d 7, 9 (2d Cir. 1990); *In re Prudential Ins. Co. of Am. Sales Practices Litig.*, 170 F. Supp. 2d 1346, 1347-48 (J.P.M.L. 2001). Plaintiffs in *Payton* withdrew their motion to remand on July 31, 2014.

---

\* Judge Ellen Segal Huvelle took no part in the decision of this matter.

<sup>1</sup> Responding defendants include: Fresenius Medical Care Holdings, Inc. d/b/a Fresenius Medical Care North America, Inc.; Fresenius USA, Inc.; Fresenius USA Manufacturing, Inc.; and Fresenius USA Marketing, Inc.


<sup>2</sup> Panel Rule 2.1(d) expressly provides that the pendency of a conditional transfer order does not limit the pretrial jurisdiction of the court in which the subject action is pending. Between the date a remand motion is filed and the date that transfer of the action to the MDL is finalized, a court wishing to rule upon the remand motion generally has adequate time in which to do so. Here, consideration of the remand motion in *Ajaryan* has been stayed pending the transferee court's decision of similar remand motions brought by plaintiffs in MDL No. 2428.

-2-

After considering all argument of counsel, we find that these actions involve common questions of fact with the actions previously transferred to MDL No. 2428, and that transfer will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. In our order centralizing this litigation, we held that the District of Massachusetts was an appropriate Section 1407 forum for actions sharing factual questions arising out of allegations that plaintiffs suffered injury or death caused by the use of GranuFlo Acid Concentrate (GranuFlo) or NaturaLyte Liquid Acid Concentrate (NaturaLyte) during hemodialysis, which allegedly may cause metabolic alkalosis in patients resulting in low blood pressure, hypokalemia, hypoxemia, hypercapnia, cardiac arrhythmia, or cardiopulmonary arrest. *See In re Fresenius GranuFlo/NaturaLyte Dialysate Prods. Liab. Litig.*, 935 F. Supp. 2d 1362 (J.P.M.L. 2013). Both of the actions listed on Schedule A involve similar allegations that plaintiffs or their decedents suffered metabolic alkalosis as a result of the use of GranuFlo and/or NaturaLyte. These actions also likewise involve factual questions relating to whether these products were defectively designed or manufactured, whether Fresenius, the manufacturer of these dialysate products, knew or should have known of the alleged propensity of these products to cause injury, and whether it provided adequate instructions and warnings with these products.

IT IS THEREFORE ORDERED that pursuant to 28 U.S.C. § 1407, the actions listed on Schedule A are transferred to the District of Massachusetts and, with the consent of that court, assigned to the Honorable Douglas P. Woodlock for inclusion in the coordinated or consolidated pretrial proceedings.

PANEL ON MULTIDISTRICT LITIGATION



---

John G. Heyburn II  
Chairman

Marjorie O. Rendell  
Lewis A. Kaplan  
R. David Proctor

Charles R. Breyer  
Sarah S. Vance

**IN RE: FRESENIUS GRANUFLO/NATURALYTE  
DIALYSATE PRODUCTS LIABILITY LITIGATION**

MDL No. 2428

**SCHEDULE A**

Central District of California

AJARYAN, ET AL. v. FRESENIUS USA, INC., ET AL., C.A. No. 2:14-02896

Eastern District of Missouri

PAYTON, ET AL. v. FRESENIUS USA, INC., ET AL., C.A. No. 4:14-00937